Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaktsiinid - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 ja 5. 1 in product information document). kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaktsiinid - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Euroopa Liit - eesti - EMA (European Medicines Agency)

biomarin international limited - recombinant human n-acetylgalactosamine-6-sulfatase - mukopolüsahhariidoos iv - muud alimentary seedetrakti ja ainevahetust tooted, - vimizim on näidustatud mukopolüsahharidoosi, iva tüübi (morquio a sündroom, mps iva) raviks igas vanuses patsientidel.

Euroopa Liit - eesti - EMA (European Medicines Agency)

dompe farmaceutici s.p.a. - recombinant human nerve growth factor - keratiit - oftalmoloogilised vahendid - mõõduka (püsiva epiteeli defekti) või raske (sarvkesta haavandi) neurotroofse keratiidi ravi täiskasvanutel.

Euroopa Liit - eesti - EMA (European Medicines Agency)

biopartners gmbh - recombinant human interferon alfa-2a - c-hepatiit, krooniline - immunostimulants, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.

Euroopa Liit - eesti - EMA (European Medicines Agency)

zoetis belgium sa - dibotermiin alfa - luu morfogeneetilised valgud - koerad - osteoinduktiivne aine, mida kasutatakse pikkade luumurdude raviks standardse kirurgilise hoolduse lisana, kasutades koertel avatud luumurdude vähenemist.

Euroopa Liit - eesti - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - rekombinantse vesikulaarset stomatiiti viirus (tüvi, indiana), mille kustutamise ümbrik glükoproteiini asendada zaire ebolavirus (tüvi kikwit 1995) pinna glükoproteiin - hemorraagiline palavik, ebola - vaktsiinid - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. kasutada ervebo peab olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - sigalaste immunoloogilised omadused - sead (nuumamiseks) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.